Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Acrocephalosyndactylia 5Cholangiocarcinoma 4Neoplasm Metastasis 3Carcinoma, Transitional Cell 3Recurrence 2Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Unknown Primary 1Myeloproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Liposarcoma 1Leukemia, Myeloid, Acute 1Glioma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Eosinophilia 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 51fludarabine 37Dexamethasone 35venetoclax 30pembrolizumab 25Rituximab 20pomalidomide 18Lenalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 12carfilzomib 11Temozolomide 11Injections 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Cisplatin 9Bortezomib 9Azacitidine 9selinexor 8Vincristine 8Immunotherapy, Adoptive 8obinutuzumab 7cemiplimab 7Drug Therapy 7Carboplatin 7zanubrutinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × pemigatinib × 1 year × Clear all
NCT06300528 2025-12-03

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

University of Utah

Phase 2 Recruiting
27 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05253807 2025-08-05

FIGHT-210

Incyte Corporation

Phase 2 Completed
8 enrolled 13 charts
Thoracic

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡